Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoposide + Anlotinib + Envafolimab in First-line Elderly SCLC
NCT05685550Phase 2Active, not recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab, anlotinib, etoposide in small cell lung cancer (SCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Apr 2023; status: active, not recruiting.
02
Drugs
envafolimabanlotinibetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05685550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685550.